Orbicular’s Ozempic generic gets U.S. FDA tentative nod

A generic mentation of Ozempic (semaglutide injection) developed by Hyderabad-based Orbicular Pharmaceutical Technologies successful concern with Florida-headquartered Apotex Corp. has received tentative support from the U.S. Food and Drug Administration (FDA).

The merchandise volition beryllium marketed and commercialised successful the U.S. by Apotex, which is the ANDA applicant, analyzable peptide-based generics developer Orbicular said successful a release.